echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The next new 1 billion injection will be born and Osaikang will enter the game strongly

    The next new 1 billion injection will be born and Osaikang will enter the game strongly

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 26, Osaikang submitted an application for the imitation of Roxatidine Hydrochloride Acetate Hydrochloride for Injection and was accepted.


    Figure 1: The latest products declared by Osaikang

    Source: CDE official website

    The commonly used H2 receptor antagonists in clinic are divided into four generations: the first generation cimetidine, the second generation ranitidine, the third generation famotidine, rosatidine is the fourth generation, and its bioavailability It is the highest among this class of drugs and is a selective histamine H2 receptor antagonist.


    Figure 2: Sales of Roxatidine Hydrochloride Acetate for Injection (Unit: Ten Thousand Yuan)

    Source: Mi Nei.


    According to data from Menet.


    At present, the approved domestic pharmaceutical companies involve Harbin Pharmaceutical Group and Beijing Sihuan Pharmaceutical.


    Table 1: Status of products declared by Osaikang since 2021

    Source: Meinenet MED2.


    Since 2021, Osaikang has also declared that a Class 1 new drug has been approved for clinical use, and dexlansoprazole for injection of a Class 2.


    Source: CDE official website, Minet database

    The review data statistics are as of September 27, if there are any errors or omissions, please correct me


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.